Originally published on Substack.
Sublingual immunotherapy aka SLIT for the treatment of allergies has been well-studied. In fact, at the current moment on pubmed.gov, there are more published clinical and randomized controlled trials for the search terms allergies and sublingual immunotherapy (409) than there are for allergies and subcutaneous immunotherapy (338). Subcutaneous or injection immunotherapy is also commonly known as SCIT.
Below are pivotal studies and reviews that highlight the key features of SLIT including its History, Safety, Efficacy, Duration and Use in Children. Also included are articles that have examined large bodies of evidence and make comparisons between SLIT and SCIT.
Lastly, there are articles included which address medication compounding and off-label prescribing. These are common practices whereby the clinician, after fully evaluating the patient’s clinical picture and the risk/benefit profile of a particular medication, prescribes a therapy that may deviate from standard guidelines. The prescribing of SLIT drops to treat environmental allergies is a classic example. In a hypothetical case that is extremely common, a clinician evaluates a patient with debilitating animal and tree pollen allergies who travels frequently for work. Given the fact that SLIT tablets do not address animal or tree pollen allergies and this patient cannot routinely show up to a physician’s office for SCIT injections due to their work schedule, SLIT drops are an ideal immunotherapy option.
https://onlinelibrary.wiley.com/doi/epdf/10.1111/all.14113
A historical description of Allergy Drops including its inception, current treatment concepts and future applications.
In the 1980s, sublingual immunotherapy was investigated as an alternative to subcutaneous immunotherapy due to safety concerns and deaths that were reported in the UK and US. Scadding et al performed the first controlled SLIT trial in 1986 with encouraging results and several others followed. As a result, SLIT has gained acceptance in the allergy world with 2 World Allergy Organization position papers (2009 and 2014) and 1 European Allergy position paper (2018) dedicated to its use. It has also been recognized as an add-on therapy for asthma by the Global Initiative for Asthma (GINA) document in 2017. See references below for these pivotal documents
Sublingual Immunotherapy: World Allergy Organization Position Paper 2009
Canonica GW, Bousquet J, Casale T, Lockey R, Baena-Cagnani C et al. Sublingual Immunotherapy: World Allergy Organization position paper 2009. World Allergy Organization Journal. 2009;2(11):223-281.
Sublingual immunotherapy: World Allergy Organization Position Paper 2013 Update
Canonica GW, Cox L, Pawankar R, Baena-Cagnani CE, Blaiss M et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organization Journal 2014; 7:6 (28 March). doi:10.1186/1939-4551-7-6
2017 GINA Report, Global Strategy for Asthma Management and Prevention https://ginasthma.org/wp-content/uploads/2019/04/wmsGINA-2017-main-report-final_V2.pdf
“The changing outlook of physicians toward SLIT in the United States is illuminated by a 2019 survey of practicing allergists, where 73.5% reported using SLIT for patients, in comparison to 5.9% a decade earlier.”
“Currently there are no safety concerns about SLIT. The more recent systematic reviews considered systemic reactions extremely rare and anecdotal among SLIT patients.”
“No serious adverse event was reported in the studies monitored, confirming the good safety profile of the sublingual-swallow method both in children and adults with rhinitis or moderate asthma.”
“The results of this study, performed in a real situation of clinical practice, confirm the satisfactory safety profile of SLIT.”
https://doi.org/10.1016/j.jaip.2016.09.017.
https://www.sciencedirect.com/science/article/pii/S2213219816304147
“Liquid sublingual allergen immunotherapy (SLIT) has been used off-label for decades, and Food and Drug Administration (FDA)-approved grass and ragweed SLIT tablets have been available in the United States since 2014. Potentially life-threatening events from SLIT do occur, although they appear to be very rare... Surveillance data for off-label liquid SLIT (nonstandardized and generally multiallergen) in the United States identified 45 SARs in 3343 patients (1.4% of patients) between 2012 and 2013, including 9 grade 2 SARs (0.3% of patients) and 1 grade 3 SAR (0.03% of patients)...off-label SLIT drops do allow for a slow build-up in highly sensitive patients, whereas SLIT tablets, with the exception of Oralair in children, do not.”
“A 2012 review by Calderon et al. estimated the anaphylaxis rate of SLIT to be 1 per 100 million doses, or 1 per 526,000 treatment years.”
“SLIT is safe and effective, and offers a convenient alternative to injection immunotherapy for appropriate patients with allergic rhinitis.”
“This is the first successful North American confirmatory phase 3 clinical trial to demonstrate the safety and efficacy of a sublingual standardized ragweed allergen immunotherapy liquid extract for the treatment of [allergic rhinitis]. During the entire ragweed season, there was a 43% decrease in [allergy symptoms].” Subjects n=218 treated with Ragweed sublingual immunotherapy ages between 18-55 years old.
“The studies (160) found that AIT and where defined both SLIT and SCIT, were more effective than standard care including pharmacotherapy. The studies that compared SLIT and SCIT gave very mixed results not allowing a clear conclusion to be drawn that either treatment was necessarily more effective or more costly than the other from a health system perspective.”
“The literature suggests that, overall, SLIT is clinically effective in rhinoconjunctivitis and asthma, although differences exist among allergens. Some open, controlled trials suggested that the clinical efficacy of SLIT is similar to that of injection immunotherapy.
https://www.jacionline.org/article/S0091-6749(18)31720-2/fulltext
“Primary efficacy results demonstrated a significant (P < .0001) and clinically relevant (32%) reduction in the combined symptom and medication score compared with placebo after 3 to 6 months of SLIT. Significantly better rhinoconjunctivitis quality-of-life scores (P < .0001) and the patient's own overall assessment of his or her health status, including the visual analog scale score (Euro Quality of Life Visual Analogue Scale; P = .0025), were also demonstrated.”
https://www.jacionline.org/article/S0091-6749(13)00507-1/fulltext
“In this (52 week) trial, ragweed AIT of 12 Amb a 1-U effectively reduced symptoms and rescue medication use in subjects with ragweed-induced AR/C and was well tolerated. This study's efficacy and safety findings support the use of self-administered ragweed AIT in the treatment of AR/C induced by this prevalent aeroallergen.”
“Seventy-eight patients were enrolled, and 59 completed the study. In the 12 control subjects no relevant change in clinical scores was seen throughout the study. In the patients receiving SLIT for 3 years, the clinical benefit persisted for 7 years. In those receiving immunotherapy for 4 or 5 years, the clinical benefit persisted for 8 years. New sensitizations occurred in all the control subjects over 15 years and in less than a quarter of the patients receiving SLIT (21%, 12%, and 11%, respectively). The second course of vaccination induced a benefit more rapidly than the first course.”
“Study to investigate sustained efficacy and disease modification in a 5-year double-blind, placebo-controlled trial, including 2 years of blinded follow-up after completion of a 3-year period of treatment with the SQ-standardized grass allergy immunotherapy tablet.” Subjects n=238 “The results confirm disease modification by SQ-standardized grass allergy immunotherapy tablet in addition to effective symptomatic treatment of allergic rhinoconjunctivitis.
“House Dust Mite (HDM) SLIT can effectively alleviate total nasal symptom scores (TNSS) and total medication scores (TMS) in children with Perennial Allergic Rhinitis (PAR).”
This review article cites several studies involving House Dust Mite (HDM) SLIT efficacy in children as young as 3 yo with allergic rhinitis as well as asthma. The article also addresses optimism by citing studies showing that HDM SLIT has the potential to prevent asthma and new allergic sensitization. “SLIT for house dust mite is an active area of ongoing research and investigation, and there is emerging and convincing data to be optimistic about this treatment option in the immediate future. Because of the noted safety and patient convenience of SLIT, this approach will offer an additional approach for an effective form of therapy (for children).”
https://www.jacionline.org/action/showPdf?pii=S0091-6749%2815%2903112-7
“Allergen immunotherapy is effective in patients with allergic rhinitis (AR) and, unlike antiallergic drugs, has been shown to modify the underlying cause of the disease, with proven long-term benefits. Subcutaneous immunotherapy (SCIT) has been the gold standard, whereas sublingual immunotherapy (SLIT) has emerged as an effective and safe alternative”
“In recent meta-analyses, there is no significant difference in the efficacy between the two treatments”
“The efficacy of SCIT and SLIT is similar in respiratory allergy, providing, based on the induction of typical changes in the immunologic response, an early control of symptoms that steadily increases during the treatment and its efficacy lasts after the recommended duration of three years. Such results are the reason why SCIT and SLIT have economic advantage over symptomatic drugs.”
https://www.annallergy.org/article/S1081-1206(18)30576-3/fulltext
This 2018 Review article in the Annals of Allergy, Asthma and Immunology highlights SLIT as a “well-validated alternative to SCIT.” Evidence of SLIT's efficacy over placebo for seasonal as well as year-round allergies in several large trials are cited.
This review and metaanalysis of 160 immunotherapy studies specifically focuses on allergic rhinitis symptoms and medication scores. SLIT and SCIT significantly reduced both scores yet no significant difference in reduction was noted when comparing SLIT and SCIT head to head.
“Off-label use of sublingual drops prepared from commercial allergen extracts is widely practiced in the United States. Commercial aqueous extract products are not FDA approved for sublingual administration, and these have not been rigorously studied in double-blind placebo-controlled studies. Thus effective and safe dose ranges have not been characterized for commercial aqueous allergen extracts (marketed for SCIT) used in the preparation of nonapproved SLIT drops.”
“Off-label medication use accounts for an estimated 50% of medication prescribing. The purpose of off-label use is to benefit an individual patient.”
Clinical studies referenced above are intended to provide information about allergy immunotherapy. These studies have not been reviewed by the FDA.
